Modus Therapeutics (Sweden)

Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis/septic shock and other disorders with severe systemic inflammation such as severe malaria, as well as states of anemia, related to chronic inflammation such as kidney disease.

Basic Information

Documented Facts

Evidence and Sources

Citation Guidance

Explore business profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Modus Therapeutics (Sweden).

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis/septic shock and other disorders with severe systemic inflammation such as severe malaria, as well as states of anemia, related to chronic inflammation such as kidney disease.

Available profile information

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.